EarthNeuZ

  We are committed to doing all we can to respond to the COVID-19 pandemic and engaged with BioNTech on a potential coronavirus vaccine. Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they're developing jointly is on target to be submitted for regulatory review in early October, as they released additional data from an early-stage study. The companies stated that the vaccine was well tolerated in less than 20% of participants with mild to moderate fever. They said the companies continued to release data from Phase I trials in the US and Germany. Confirmation of their October goal, previously announced last month, would make the vaccine the fastest-paced in the world. Some analysts expect the use of the vaccine to be approved in the US by November. Pfizer and BioNTech signed a $2 billion deal last month to supply the initial 100 million doses of the vaccine. experimental candidates in hopes of stabilizing local economies and preventing the spread of the virus which has alread...